Biologics License Application submitted to FDA for Loncastuximab Tesirine for treatment of relapsed or refractory diffuse large B-cell lymphoma

Submission for this antibody drug conjugate composed of monoclonal antibody directed against human CD19 and conjugated to a pyrrolobenzodiazepine dimer cytotoxin is based on data from phase II LOTIS 2, trial in patients who have received ≥2 lines of prior systemic therapy.

Source:

Biospace Inc.